SLN vs. CVAC, PAHC, ORIC, LYEL, PHAR, ZYME, BCYC, NUVB, NRIX, and OLMA
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include CureVac (CVAC), Phibro Animal Health (PAHC), ORIC Pharmaceuticals (ORIC), Lyell Immunopharma (LYEL), Pharming Group (PHAR), Zymeworks (ZYME), Bicycle Therapeutics (BCYC), Nuvation Bio (NUVB), Nurix Therapeutics (NRIX), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical preparations" industry.
CureVac (NASDAQ:CVAC) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.
Silence Therapeutics has a net margin of -171.41% compared to Silence Therapeutics' net margin of -483.85%. Silence Therapeutics' return on equity of -41.87% beat CureVac's return on equity.
CureVac presently has a consensus target price of $8.33, indicating a potential upside of 138.78%. Silence Therapeutics has a consensus target price of $57.25, indicating a potential upside of 148.91%. Given CureVac's stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than CureVac.
Silence Therapeutics has lower revenue, but higher earnings than CureVac. Silence Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
In the previous week, Silence Therapeutics had 6 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Silence Therapeutics and 2 mentions for CureVac. CureVac's average media sentiment score of 0.64 beat Silence Therapeutics' score of 0.25 indicating that Silence Therapeutics is being referred to more favorably in the news media.
17.3% of CureVac shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Silence Therapeutics received 1 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 71.88% of users gave Silence Therapeutics an outperform vote while only 51.16% of users gave CureVac an outperform vote.
CureVac has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Summary
Silence Therapeutics beats CureVac on 12 of the 18 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
